Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

EAST HANOVER, N.J., Nov. 7, 2011 /PRNewswire/ -- Novartis announced today new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001)[1].

The results of the study, which met both primary endpoints, will be presented on November 9th at the American College of Rheumatology's (ACR) Annual Scientific Meeting in Chicago, US[1].

"The treatment of SJIA is a challenge given our current treatment options. Despite our best efforts, optimal disease control is often times elusive. We still must use steroids in the treatment of these children with SJIA. Steroids help manage many SJIA symptoms, such as fever and inflammation, but doctors try to minimize their use because of the potential negative impact on bones and growth," said Daniel Lovell, M.D., one of the study investigators and Professor of Pediatrics at the Cincinnati Children's Hospital Medical Center. "These data are exciting because they show that patients on ACZ885 were able to reduce their steroid use, and also experienced excellent disease control."

In addition, patients with SJIA on ACZ885 were nearly three times (0.37 hazard ratio) less likely to suffer a new flare. Therefore, only 27% of ACZ885-treated patients experienced a new flare, vs. 75% of patients on placebo during the study (p=0.0043)[1].

Data from this trial supports the safety and efficacy profile of ACZ885 in the study population. These results, along with data from a second pivotal study, are planned to form the basis for worldwide regulatory submissions in 2012. Side effects observed in this study were similar to those already seen for ACZ885's approved indication, including infections and neutropenia[1]. In addition, cases of macrophage activation syndrome (MAS) were reported in this study[1]
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 ... environments. Human exploration of space requires astronauts to maintain ... safety and success, and prevent potential errors and accidents. ... little is known about how cognition is affected by ... affected. Now, Penn Medicine researchers are poised ...
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
(Date:11/26/2014)... 2014 SonaCare Medical, a leading ... devices, recently participated in the American Urology Association’s ... .” Key opinion leaders in urology presented on ... small renal masses while attendees had the opportunity ... in hands-on labs. Attendees at the Los Angeles, ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2
... announces that a new market research report is ... Adds Global Top 10 Biotechnology Companies -- Industry, ... http://www.reportlinker.com/p0155124/Reportlinker-Adds-Global-Top-10-Biotechnology-Companies----Industry-Financial-and-SWOT-Analysis.html ... Companies Report: Strategic evaluation of industry and key ...
... October 16 , - New ... Brain Science and Used by the National Institutes of,Health, Will ... Elsevier, the leading publisher of scientific, ... showcase the new,features it is rolling out for its BrainNavigator ...
... Texas A team of scientists, led by a biomedical ... for the first time that mathematical models created ... correctly predict previously unknown cellular mechanisms. This brings biologists a ... control the inner workings of the cell as readily as ...
Cached Biology Technology:Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis 2Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis 3Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis 4Reportlinker Adds Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis 5Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 2Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 3Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 4Elsevier's BrainNavigator Research Tool to Launch new Features at Neuroscience 2009 Show 5Scientists use math modeling to predict unknown biological mechanism of regulation 2
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Morphine, as little as a single dose, blocks the brain’s ... Brown University research published in Nature. , The findings, uncovered ... explain the origins of addiction in the brain. The research ... disease of learning and memory. , "We’ve added a ...
... Dutch researcher Harm Veling has demonstrated that our brains fend ... disrupting external influences. If we are tired, we can no ... brain selects incoming information to remember useful things. Distracting information ... of tiredness, this system no longer seems to work. ...
... One out of three sexually active older adults infected with ... University researchers. A survey of 260 HIV-positive older adults found ... and were in a relationship. , AIDs cases among the ... for Disease Control and Prevention, they will account for half ...
Cached Biology News:Morphine makes lasting -- and surprising -- change in the brain 2Molecular tools make the cut 21/3 of sexually active older adults with HIV/AIDs has unprotected sex 2
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Biology Products: